Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/17/2018 |
| Start Date: | August 14, 2017 |
| End Date: | April 1, 2022 |
| Contact: | Marilyn Donaldson, RN |
| Email: | marilyn.donaldson@louisville.edu |
| Phone: | 502-629-3323 |
Compare the efficacy and tolerability of irreversible electroporation in combination with
Nivolumab in patients with locally advanced pancreatic cancer.
Nivolumab in patients with locally advanced pancreatic cancer.
Immunotherapy and irreversible electroporation in the treatment of advanced pancreatic
adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible
electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab
post-operatively.
adenocarcinoma. This is a Phase II study in which all patients undergoing irreversible
electroporation of locally advanced pancreatic adenocarcinoma will be treated with nivolumab
post-operatively.
Inclusion Criteria:
- ≥ 18 years if age
- Diagnosed with stage III pancreatic cancer
- Tumor is measurable
- Glomerular Filtration Rate > 60 m/L/min/1.73 m(2)
- Willing and able to comply with the protocol requirements
- Able to comprehend and have signed the informed consent to participate
Exclusion Criteria:
- Participating in another clinical trial for the treatment of cancer at time of
screening
- Are pregnant or currently breast feeding
- Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that
cannot be deactivated during the procedure
- Have non-removable implants with metal parts within 1 cm of the target lesion
- Had a myocardial infarction within 3 months prior to enrollment
We found this trial at
1
site
University of Louisville The University of Louisville is a state supported research university located in...
Click here to add this to my saved trials
